SNGX
Soligenix, Inc.
$0.38
-0.01 (-2.56%)
At close · Jul 6
Market Cap
$5.72M
Shares
14,824,174
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$119.37K
0%
FY2025
Net Income
-$11.08M
-34%
FY2025
Gross Margin
81.52%
+69.9pp
FY2024
Operating Margin
-9923.24%
-2015.5pp
FY2025
Diluted EPS
-$2.14
+57%
FY2025
Operating Cash Flow
-$10.27M
-22.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $119.37K | $119.37K | $839.36K | $948.91K | $824.27K | $2.36M | $4.63M | $5.24M | $5.43M | $10.45M | $8.77M | $7.04M | $3.22M | $3.14M | $7.66M | |
| -$850.54K | — | — | — | — | -$862.58K | -$10.88K | — | — | — | $2216 | -$8017 | — | — | — | — | |
| — | $119.37K | $119.37K | $742.05K | $550.82K | $728.64K | $1.82M | $3.57M | $4.6M | $4.31M | $8.43M | $6.88M | $5.31M | $2.54M | $2.59M | $2.11M | |
| — | — | $97.31K | $97.31K | $398.09K | $95.63K | $538.5K | $1.06M | $643.73K | $1.12M | $2.02M | $1.89M | $1.73M | $679.87K | $551.55K | $5.55M | |
| — | — | 81.52% | 11.59% | 41.95% | 11.6% | 22.82% | 22.95% | 12.28% | 20.66% | 19.29% | 21.51% | 24.55% | 21.09% | 17.54% | 72.49% | |
| $7.33M | $7.49M | $5.22M | $3.31M | $7.94M | $8.39M | $10.15M | $8.12M | $6.75M | $5.51M | $4.3M | $5.4M | $5.09M | $5.07M | $2.61M | $6.27M | |
| $4.38M | $4.36M | $4.22M | $4.48M | $6.69M | $4.85M | $3.98M | $3.48M | $2.95M | $3.21M | $3.43M | $3.6M | $3.4M | $2.77M | $2.63M | $2.24M | |
| — | — | — | — | — | — | $19.7K | $27.16K | $27.09K | $52.68K | $62.1K | $221.22K | $222.56K | $223.22K | $223.84K | — | |
| $33.49K | — | — | — | — | $34.16K | $62.37K | $54.45K | $44.06K | $68.56K | $89.93K | $247.46K | $245.79K | $230.07K | $230.63K | $226.03K | |
| $11.7M | $11.85M | $9.44M | $7.8M | $14.64M | $13.24M | $19.13M | $11.6M | $9.7M | $8.72M | $7.72M | $9M | $12.49M | $7.84M | $5.24M | $8.51M | |
| -$11.7M | -$11.85M | -$9.44M | -$7.7M | -$14.24M | -$13.14M | -$18.59M | -$10.54M | -$9.06M | -$7.59M | -$5.71M | -$7.11M | -$10.76M | -$7.16M | -$4.69M | -$2.96M | |
| — | -9923.24% | -7907.7% | -917.12% | -1500.55% | -1594.25% | -787.75% | -227.67% | -172.83% | -139.79% | -54.64% | -81.09% | -152.79% | -221.97% | -149.16% | -38.63% | |
| -$15.07M | — | — | — | — | -$13.11M | -$18.52M | -$10.49M | -$9.01M | -$7.53M | -$5.62M | -$6.86M | -$10.52M | -$6.93M | -$4.46M | -$2.73M | |
| $51.81K | — | — | — | — | — | — | $148.97K | — | — | — | — | $1310 | $1960 | $6202 | $7444 | |
| $243.11K | $258.48K | $763.81K | -$210.59K | -$714.37K | -$274.83K | $61.09K | $574.75K | — | $29.91K | $1.93M | -$1.21M | $3.44M | -$3.65M | $6202 | $7444 | |
| -$11.46M | -$11.59M | -$8.68M | -$7.91M | -$14.95M | -$13.42M | -$18.53M | -$9.97M | -$8.9M | -$7.56M | -$3.78M | -$8.32M | -$7.32M | -$10.81M | -$4.68M | -$2.95M | |
| — | -$506.62K | -$409.11K | -$1.77M | -$1.15M | -$864.74K | -$836.89K | -$610.68K | -$416.81K | -$416.81K | -$530.14K | -$488.93K | -$616.87K | -$750.36K | -$521.46K | -$574.16K | |
| -$10.95M | -$11.08M | -$8.27M | -$6.14M | -$13.8M | -$12.55M | -$17.69M | -$9.36M | -$8.9M | -$7.15M | -$3.25M | -$7.83M | -$6.71M | -$10.06M | -$4.16M | -$2.38M | |
| — | -9282.3% | -6925.11% | -731.6% | -1454.12% | -1522.68% | -749.69% | -202.07% | -169.8% | -131.56% | -31.06% | -89.31% | -95.23% | -311.99% | -132.39% | -31.04% | |
| -$10.95M | -$11.08M | -$8.27M | -$6.14M | -$13.8M | -$12.55M | — | — | — | -$7.15M | -$3.25M | -$7.83M | -$6.71M | — | — | — | |
| — | -$11.08M | -$8.24M | -$6.14M | -$13.82M | -$12.48M | -$17.67M | -$9.4M | -$8.9M | — | — | — | — | — | — | — | |
| USD/shares | — | -$2.14 | -$4.98 | -$12.64 | -$76.96 | -$74.40 | — | — | — | -$278.40 | -$223.20 | -$72.00 | -$76.80 | — | — | — |
| USD/shares | — | -$2.14 | -$4.98 | -$12.64 | -$76.96 | -$74.40 | — | — | — | -$278.40 | -$321.60 | -$72.00 | -$103.20 | — | — | — |
| shares | — | 5.19M | 1.66M | 484.88K | 179.46K | 167.22K | 114.53K | 80.74K | 54.91K | 25.6K | 14.51K | 108.61K | 85.99K | 64.43K | 46.4K | — |
| shares | — | 5.19M | 1.66M | 484.88K | 179.46K | 167.22K | 114.53K | 80.74K | 54.91K | 25.6K | 14.93K | 108.61K | 98.27K | 64.43K | 46.4K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Bio Therapeutics | $117,369 | — | $31,929 | $395,124 | $119,371 |
| Public Health Solutions | — | $824,268 | $916,982 | $444,235 | — |
| Vaccines Bio Defense | $2,242,078 | — | — | — | — |
By Product & Service (USD)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Grant | $428,914 | $790,917 | $698,911 | $839,359 | $119,371 |
| Government Contract | $1,930,533 | $33,351 | — | — | — |
| License | — | — | $250,000 | — | — |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|---|---|
| Public Health Solutions | — | -$542,270 | $26,612 | -$36,531 | -$254,576 | -$88,769 |
| Bio Therapeutics | -$13,610,715 | -$7,216,450 | -$7,614,988 | -$2,812,303 | -$4,365,034 | -$6,981,971 |
| Vaccines Bio Defense | -$85,417 | -$647,600 | — | — | — | — |
| Corporate | -$4,890,375 | -$5,212,349 | — | — | — | — |
Operating Margin by Segment (%)
| Component | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|---|---|
| Bio Therapeutics | -11596.5% | — | -23849.8% | -711.8% | -3656.7% |
| Public Health Solutions | — | -65.8% | 2.9% | -8.2% | — |
| Vaccines Bio Defense | -3.8% | — | — | — | — |